Status:
COMPLETED
Three-Dose Regimen of MRKAd5+6 Trigene (V526) in Healthy Adults (V526-001)(COMPLETED)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
HIV
HIV Infections
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
A study to assess the general safety and tolerability of the administration of the 3-dose regimen of the MRKAd5+6 trigene vaccine
Eligibility Criteria
Inclusion
- Subject has negative tests for HIV, Hepatitis B, and Hepatitis C within 60 days of injection
- Subject agrees to use an acceptable method of birth control through week 52 of the study
Exclusion
- Subject has been given immune globulin or blood products within 30 days of first dose of study vaccine
- Subject has been vaccinated with a live virus vaccine within 30 days or an inactivated vaccine within 5 days of first dose of study vaccine
- Subject has known or suspected impaired immune function
- Subject has participated in any other HIV vaccine trial
- Female subject is pregnant or breastfeeding
Key Trial Info
Start Date :
April 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2011
Estimated Enrollment :
147 Patients enrolled
Trial Details
Trial ID
NCT00850616
Start Date
April 1 2005
End Date
March 1 2011
Last Update
November 2 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.